API- Abacavir Lamivudine

Packaging- Tablets

Strength- 600mg/300mg

Get an Enquiry


Abacavir Lamivudine, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, is used in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Dosage and Side Effects

The recommended dosage of Abacavir Lamivudine for adults and pediatric patients weighing at least 25 kg is one tablet (600mg/300mg) taken orally once daily, along with other antiretroviral agents, with or without food. Prior to prescribing these tablets, assess pediatric patients for their ability to swallow pills.

The most commonly reported side effects due to Abacavir Lamivudine include insomnia, drug hypersensitivity, depression/depressed mood, nausea, headache/migraine, fatigue/malaise, dizziness/vertigo, and diarrhea.

Warning and Precautions

  • Prior to initiating treatment with abacavir lamivudine combination medicine, screen for the HLA-B*5701 allele because of abacavir.
  • Use of Abacavir Lamivudine is restricted in patients who have the HLA-B*5701 allele, with prior hypersensitivity reaction to abacavir or lamivudine, with moderate or severe hepatic impairment.
  • Serious and sometimes fatal hypersensitivity reactions may occur. These reactions included multi-organ failure and anaphylaxis and typically occur within the first 6 weeks of treatment with abacavir; although abacavir hypersensitivity reactions may occur any time during treatment.
  • Clinical and laboratory evidence of exacerbations of hepatitis may occur after discontinuation of lamivudine. Patients should be precisely monitored with both clinical and laboratory follow-up for at least some months after stopping treatment.
  • Suspend treatment with Abacavir Lamivudine in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity, which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations.
  • Instruct women with HIV-1 infection not to breastfeed while taking treatment with abacavir lamivudine 600 mg / 300 mg because HIV-1 can be passed to the baby in breast milk.


What is Abacavir Lamivudine?

Abacavir lamivudine (Kivexa 600 mg), is a fixed-dose combination antiretroviral medication authorized for the treatment of HIV/AIDS.

What dosage strengths Abacavir Lamivudine is supplied?

Abacavir Lamivudine is supplied in 600mg/300mg dosage strengths.

How is Abacavir Lamivudine administered?

Abacavir Lamivudine is a kind of fixed-dose combination medicine that typically comes in the form of a tablet for oral administration.

What type of drug is Abacavir Lamivudine?

Abacavir Lamivudine specifically is a type of drug called nucleoside reverse transcriptase inhibitors (NRTIs).